MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
Clinical trial NCT07409454 · RECRUITING
Trial details
- NCT number
- NCT07409454
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-07
- Primary completion
- 2027-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.